汉森制药(002412.SZ)发布上半年业绩，归母净利润6853.84万元，下降31.80%

Core Viewpoint - Hansen Pharmaceutical (002412.SZ) reported a revenue of 509 million yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [1] - The net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 31.72% to 64.77 million yuan [1] - Basic earnings per share stood at 0.1362 yuan [1] Financial Performance - Revenue for the first half of 2025: 509 million yuan, up 5.91% year-on-year [1] - Net profit attributable to shareholders: 68.54 million yuan, down 31.80% year-on-year [1] - Net profit after deducting non-recurring items: 64.77 million yuan, down 31.72% year-on-year [1] - Basic earnings per share: 0.1362 yuan [1]